Bacteria: Gram-negative

Proteus mirabilis and Proteus vulgaris

Proteus mirabilis; Proteus vulgaris

General medical information for education only, not medical advice. Treatment considerations summarize published guidance at drug-class level; therapy is chosen by the treating clinician using susceptibility results, local resistance patterns and current guidelines.

Overview

Motile, urease-producing Gram-negative rods. Urease raises urine pH, which promotes struvite stones and catheter encrustation.

Infections

Complicated and catheter-associated urinary tract infection, urinary stones, wound infection, bloodstream infection.

Signs and symptoms

Urinary symptoms; recurrent catheter blockage; flank pain with stones.

Antibiotic and antimicrobial resistance

Intrinsically resistant to nitrofurantoin, colistin and tetracyclines. P. vulgaris has a chromosomal cephalosporinase; ESBL genes (ESBL genes) occur in P. mirabilis.

Treatment considerations

Guided by susceptibility testing; stones and encrusted catheters may need removal or replacement.

Concentric swarming growth of Proteus mirabilis on agar
Proteus mirabilis swarming growth (Dienes reaction). CDC PHIL (J. J. Farmer); public domain. Image source
Gram-negative rods, schematic
Gram-negative rods. Schematic, not to scale; InnovexLab.

Sources

  1. CDC. Healthcare-associated infections: diseases and organisms.
  2. CDC. ESBL-producing Enterobacterales.
  3. CDC. Carbapenem-resistant Enterobacterales (CRE).
  4. IDSA. Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections.
  5. IDSA. Complicated Urinary Tract Infections guideline.

Sources accessed November 2026. Links open external sites that InnovexLab does not control.

Medical disclaimer

This page is general educational information summarized from published public-health and professional-society guidance. It is not medical advice, a diagnosis or a treatment recommendation, and reading it does not create a clinician–patient relationship with InnovexLab. Decisions about testing, diagnosis and treatment belong to the treating clinician, using the patient’s history and examination, laboratory and susceptibility results, local resistance patterns and current guidelines. Guidance changes over time; consult the original sources for the latest version. InnovexLab provides this information as is and does not warrant that it is complete or current.

Patients with questions about their health should contact their own healthcare provider. In an emergency, call 911.

Sources, image credits and editorial policy

Discuss a testing program with InnovexLab

Review the panel that fits your patients, its specimen requirements, and how results and billing work.